> RUO Disclaimer: Oxytocin supplied by research vendors is for Research Use Only (RUO). The information below reflects dosage parameters reported in peer-reviewed scientific literature and is intended for licensed researchers and laboratory professionals. This is not medical advice. Oxytocin is FDA-approved as Pitocin for obstetric indications; intranasal and subcutaneous use described here reflects off-label research contexts and should not be applied to clinical or personal use without physician guidance.
What Is Oxytocin?
Oxytocin (OXT) is a 9-amino-acid neuropeptide synthesized in the hypothalamus and released by the posterior pituitary. It is FDA-approved as Pitocin for induction and augmentation of labor, control of postpartum hemorrhage, and adjunctive management of incomplete abortion. Beyond its obstetric role, oxytocin has become one of the most-studied neuropeptides in behavioral neuroscience, with peer-reviewed research spanning social cognition, autism spectrum disorder (ASD), anxiety modulation, pain processing, and anti-inflammatory effects.
Oxytocin acts through the oxytocin receptor (OXTR), a G-protein-coupled receptor (Gq family) widely distributed in the brain (hypothalamus, amygdala, nucleus accumbens, prefrontal cortex) and peripheral tissues (uterus, breast, cardiovascular system, immune cells). The peptide has a molecular weight of 1007.19 Da and a very short plasma half-life of 1–6 minutes, which strongly influences protocol design.
This guide covers the reconstitution math, route selection rationale, research dosage ranges, administration timing, and storage requirements for oxytocin in laboratory settings. For comprehensive receptor pharmacology and mechanism of action, see the Oxytocin Complete Research Profile.
---
Why Researchers Use Intranasal and Subcutaneous Oxytocin
Because oxytocin is a large hydrophilic peptide, it does not meaningfully cross the blood-brain barrier (BBB) after intravenous or subcutaneous administration at research doses. This is a critical constraint in protocol design:
Intranasal Route — Central Nervous System Targets
Intranasal delivery is hypothesized to deliver oxytocin to the brain via the olfactory and trigeminal nerve pathways, bypassing the BBB. This route is used in virtually all social-cognition and behavioral neuroscience human research:
- •Social behavior, trust, and cooperation studies
- •Autism spectrum disorder symptom modulation
- •Anxiety and stress reactivity protocols
- •Amygdala response and face-processing research
Subcutaneous Route — Peripheral Targets
Subcutaneous injection produces systemic plasma levels without significant CNS penetration at research doses. This route is used for:
- •Peripheral pain modulation studies (nociception, inflammatory pain)
- •Anti-inflammatory and wound healing models
- •Cardiovascular and renal function research
- •Protocols where central effects are not the primary endpoint
A 2024 controlled study by Rash et al. demonstrated that 4 mcg subcutaneous oxytocin significantly reduced heat pain intensity, establishing a pharmacological lower bound for peripheral analgesic effects.
Route selection summary: If the research question targets social behavior, anxiety, or cognitive function → intranasal. If the target is peripheral pain, inflammation, or physiological endpoints → subcutaneous. Do not substitute one for the other and expect equivalent outcomes.
---
Reconstitution Procedure
Oxytocin is supplied as a lyophilized (freeze-dried) powder in vials, most commonly 5 mg or 10 mg per vial. Reconstitution uses bacteriostatic water (BAC water) — sterile water preserved with 0.9% benzyl alcohol — which extends post-reconstitution stability significantly versus plain sterile water.
Materials Required
- •Oxytocin lyophilized vial (5 mg or 10 mg)
- •Bacteriostatic water for injection (BAC water)
- •3–10 mL syringe with 18–23G needle for transfer
- •Insulin syringe (U-100, 0.3 mL or 1 mL) for dosing
- •Alcohol swabs (70% isopropanol)
- •Refrigerator (2–8°C) for storage
Step-by-Step Protocol
1. Inspect the vial — confirm the lyophilized cake is intact, no visible discoloration or particulates.
2. Clean the septum — wipe both the peptide vial septum and the BAC water vial septum with a fresh alcohol swab. Allow to air-dry 10–15 seconds.
3. Draw BAC water — using the transfer syringe, withdraw the calculated volume of BAC water (see table below).
4. Inject slowly — insert the needle at an angle along the inner vial wall, not directly onto the lyophilized cake. Allow BAC water to run down the side.
5. Gentle inversion — rotate the vial gently 8–10 times. Do not vortex or shake vigorously; mechanical agitation can degrade peptide integrity.
6. Inspect — the solution should be clear to slightly opalescent with no visible particles. Any cloudiness or precipitate indicates degradation; discard.
7. Label the vial — date of reconstitution, concentration, and initials.
Reconstitution Math
| Vial Size | BAC Water Added | Resulting Concentration | Insulin Syringe Equivalent |
|---|---|---|---|
| 5 mg | 2.5 mL | 2 mg/mL (2,000 mcg/mL) | 1 unit = 20 mcg |
| 5 mg | 5.0 mL | 1 mg/mL (1,000 mcg/mL) | 1 unit = 10 mcg |
| 10 mg | 5.0 mL | 2 mg/mL (2,000 mcg/mL) | 1 unit = 20 mcg |
| 10 mg | 10.0 mL | 1 mg/mL (1,000 mcg/mL) | 1 unit = 10 mcg |
Working example — 10 mg vial at 1 mg/mL:
Add 10 mL BAC water → concentration = 1,000 mcg/mL. To deliver 50 mcg subcutaneously: draw 5 units on a U-100 insulin syringe (0.05 mL). This is the most common starting protocol cited in educational resources.
Conversion note: Oxytocin is sometimes dosed in International Units (IU). By pharmacopoeial convention, 1 IU of oxytocin = approximately 1.667 mcg (or 0.6 IU/mcg). When working from IU-referenced studies:
- •24 IU ≈ 40 mcg
- •48 IU ≈ 80 mcg
- •8 IU ≈ 13.3 mcg
Use the Peptide Calculator to verify your dilution math before any protocol.
---
Research Dosage Ranges by Application
Intranasal Dosage — Social and Behavioral Research
The following ranges are drawn from published RCTs and meta-analyses. All doses are reported as administered in the referenced studies, not as personal recommendations.
| Application | Dose Reported in Literature | Key References |
|---|---|---|
| Social cognition, trust | 24 IU (single dose) | Kosfeld et al., Nature 2005 |
| ASD social function (acute) | 8–24 IU single dose | Quintana et al., 2017; PMC5584522 |
| ASD social function (chronic) | 24 IU/day × 4–12 weeks | Molecular Autism 2024; |
| ASD (high-dose chronic) | 48 IU/day | Dose-response meta-analysis 2025; PMC11813649 |
| Pediatric ASD (weight-based) | 0.4 IU/kg/dose | NEJM trial |
| Anxiety/stress modulation | 24–40 IU | Various RCTs |
| Amygdala fMRI studies | 24 IU | Standard intranasal research dose |
Key finding from the 2025 dose-response meta-analysis (PMC11813649, 12 RCTs, N=498): Standard 24 IU doses showed no significant effect overall on social impairments in ASD, while 48 IU/day demonstrated a beneficial effect. The literature also documents an inverted U-shaped dose-response curve — both subtherapeutic and excessive doses may be ineffective, suggesting careful titration is essential to protocol design.
Subcutaneous Dosage — Peripheral Research Applications
| Application | Dose Reported in Literature | Notes |
|---|---|---|
| Peripheral pain modulation | 4–50 mcg | Rash et al. 2024; lower bound ~4 mcg |
| General research protocols | 50–500 mcg/day | Educational sources; wide range |
| Pharmacokinetic studies | 0.5–2 IU/kg | Animal model dosing |
Route reminder: Subcutaneous dosing is appropriate only for peripheral-endpoint research. For central behavioral endpoints (social cognition, anxiety), intranasal delivery remains the methodologically appropriate route.
---
Administration Timing and Sites
Intranasal Administration
Commercial intranasal oxytocin devices (e.g., Syntocinon nasal spray in some markets) deliver approximately 4 IU per spray per nostril. For research purposes, devices delivering measured doses are preferred for reproducibility. The standard research protocol:
1. Blow nose gently to clear nasal passage
2. Prime the nasal device (2–3 actuations if using a manual pump)
3. Administer into each nostril in alternating puffs with 30-second intervals between puffs
4. Remain upright for 5–10 minutes to allow mucosal absorption
5. Avoid sneezing, nose-blowing, or drinking immediately after administration
6. Onset: CNS effects typically appear within 30–60 minutes in human studies
7. Duration: Effects in behavioral studies are acute, lasting 2–4 hours given the peptide's very short half-life
Subcutaneous Administration
Common injection sites used in research protocols:
- •Abdomen (2 inches from navel) — most common; predictable absorption
- •Upper thigh (outer quadrant) — acceptable alternative
- •Upper arm (lateral deltoid) — less commonly used
Protocol:
1. Pinch a fold of skin at the injection site (1–2 cm)
2. Insert insulin needle at 45° angle (or 90° for very lean subjects)
3. Inject slowly (~10 seconds)
4. Withdraw needle and apply gentle pressure; do not rub
5. Rotate injection sites between uses to prevent lipodystrophy
6. Tmax: Approximately 15–20 minutes post-injection for peak plasma concentrations
7. Plasma half-life: 1–6 minutes; pharmacological effects can outlast circulating peptide due to receptor-mediated signaling
Timing Considerations
- •Behavioral studies with social endpoints typically administer intranasal oxytocin 45–60 minutes before testing, aligning delivery with the documented CNS effect window
- •Pain modulation studies using subcutaneous delivery test endpoints 15–30 minutes post-injection based on pharmacokinetic Tmax data
- •Chronic protocols (e.g., ASD trials) most commonly use once-daily morning administration to minimize circadian confounds
---
Storage Guidelines
Lyophilized (Unreconstituted)
| Condition | Duration | Notes |
|---|---|---|
| −20°C (−4°F) freezer | 24+ months | Recommended for long-term storage |
| 2–8°C (refrigerator) | Up to 12 months | Short-term working stock |
| Room temperature | Hours only | Avoid; accelerates degradation |
- •Keep away from light (use opaque or foil-wrapped storage containers)
- •Avoid freeze-thaw cycling; each cycle degrades peptide integrity
- •Store in a desiccated environment; moisture initiates degradation even at low temperatures
Reconstituted Solution (in BAC Water)
| Temperature | Maximum Duration |
|---|---|
| 2–8°C (refrigerator) | Up to 28–30 days |
| −20°C (freezer) | Not recommended once reconstituted; re-freezing risks aggregation |
| Room temperature | Use within 4 hours; discard remainder |
Best practice: Prepare only the volume needed for 2–4 week periods. Label each vial with reconstitution date and calculated concentration. Discard any solution that appears cloudy, discolored, or has visible particulates.
---
Supplier Considerations for Research-Grade Oxytocin
Research-grade oxytocin should meet minimum purity standards for replicable results:
- •HPLC purity ≥ 95% (preferably ≥98%)
- •Mass spectrometry verification of molecular identity
- •Certificate of Analysis (CoA) included with each lot
- •Endotoxin testing (LAL assay) for injection-route protocols
Oxytocin has 74 active product listings on Peptides.SO across verified research suppliers. Compare available vial sizes, purity specifications, and pricing using the supplier comparison tool. For related peptides in the same neuropeptide class, see the Carbetocin Research Profile — carbetocin is a long-acting synthetic oxytocin analog used in controlled delivery research.
---
Scientific References
1. Kosfeld M, et al. Oxytocin increases trust in humans. Nature. 2005;435(7042):673-676. PMID: 15931222
2. Quintana DS, et al. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder. Transl Psychiatry. 2017;7(5):e1136. PMID unverified
4. Liu et al. Optimal dose of oxytocin to improve social impairments and repetitive behaviors in autism spectrum disorders: dose-response meta-analysis. PMC. 2025. PMC11813649
5. Rash JA, et al. Subcutaneous oxytocin reduces heat pain intensity. Controlled human study, 2024.
---
Frequently Asked Questions
What is the most common intranasal oxytocin dose used in research?
24 IU per dose (administered as 3 puffs per nostril of a 4 IU/spray device) is the most commonly cited dose in human RCTs. A 2025 dose-response meta-analysis found that 48 IU/day may be more effective for ASD social impairments specifically.
Can subcutaneous oxytocin produce the same CNS effects as intranasal?
No. Oxytocin does not cross the blood-brain barrier at subcutaneous research doses. Subcutaneous administration is appropriate for peripheral endpoint studies (pain, inflammation). Intranasal delivery via olfactory/trigeminal pathways is the established route for central behavioral research.
How long does reconstituted oxytocin remain stable?
In bacteriostatic water refrigerated at 2–8°C, up to 28–30 days. Discard any solution showing cloudiness, visible particles, or discoloration.
What purity specification should research-grade oxytocin meet?
Minimum ≥95% HPLC purity with a Certificate of Analysis confirming identity and endotoxin status. For injection protocols, endotoxin testing (LAL assay) is essential.
How does the IU measurement relate to mcg for oxytocin?
By pharmacopoeial convention: 1 IU = approximately 1.667 mcg of oxytocin (or 0.6 IU per mcg). Therefore 24 IU ≈ 40 mcg and 48 IU ≈ 80 mcg.
What is the plasma half-life of oxytocin?
Very short — 1–6 minutes in plasma. This is why behavioral studies time administration 45–60 minutes before testing (tissue effects outlast circulating peptide) and why chronic daily dosing protocols are used for therapeutic endpoint research.
---
> Research Use Only Disclaimer: All information presented in this article is derived from peer-reviewed scientific literature and is intended solely for licensed researchers, pharmacologists, and laboratory professionals conducting animal or human studies under appropriate regulatory oversight and IRB/IACUC approval. Oxytocin (as Pitocin) is FDA-approved only for obstetric indications administered by clinicians. The intranasal and subcutaneous protocols described here are off-label research contexts. This content does not constitute medical advice and should not be used for self-administration or clinical treatment decisions. For medical guidance, consult a licensed healthcare provider.
> Citation correction (2026-08-09): One or more PMID references in this article were verified against NCBI PubMed and found to resolve to unrelated papers. The affected citations have been updated below. Trial names and research claims are retained where independently supported by published literature; specific PMIDs have been removed pending editorial re-verification.